PD184352 (PD-184352; CI-1040), an analog of benzhydroxamate, is an orally bioactive, specific, allosteric/non-ATP competitive MEK1/2 inhibitor with potential anticancer activity. In cell-based assays, it inhibits MEK1/2 with IC50 values of 17 nM and exhibits a 100-fold preference for MEK1/2 over MEK5. In mouse xenograft models, it exhibits strong in vitro anti-proliferative activity and significant in vivo antitumor efficacy.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.